Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop

Soligenix Inc. announced that new supportive trial data for its HyBryte photodynamic therapy in treating cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The presentations will occur ahead of the American Academy of Dermatology Annual Meeting and will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor.

The data supports HyBryte’s potential as a therapeutic option for CTCL, a rare cancer of white blood cells that primarily affects the skin. The company’s Specialized BioTherapeutics business segment is developing HyBryte, also known as SGX301 or synthetic hypericin sodium, as a novel photodynamic therapy utilizing safe visible light. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s development programs in this business segment also include expansion of synthetic hypericin into psoriasis, and development of dusquetide for treating inflammatory diseases including oral mucositis in head and neck cancer.

The company maintains a newsroom where the latest updates relating to SNGX are available at https://ibn.fm/SNGX. The full press release containing this announcement can be viewed at https://ibn.fm/iTepg. The presentation of this new data represents a significant step toward potential regulatory approval and commercialization of HyBryte for patients with cutaneous T-cell lymphoma who currently have limited treatment options.

Beyond its Specialized BioTherapeutics segment, Soligenix’s Public Health Solutions business segment includes development programs for vaccine candidates including RiVax for ricin toxin, vaccines targeting filoviruses such as Marburg and Ebola, and CiVax for prevention of COVID-19. These programs incorporate the company’s proprietary heat stabilization platform technology known as ThermoVax and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop.

The post Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop appeared first on citybuzz.